Awards and Achievements

BioMark Diagnostics Inc. is highly accomplished and recognized for its cancer research and cancer detection technology development.

early stage cancer detection - BioMark Diagnostics we believe cancer can be cured
early stage cancer detection - BioMark Diagnostics we believe cancer can be cured

Collaborations

Cancer Research Awards, Grants and Recognitions

BioMark has received funding from many government agencies including:

  • NRC IRAP
  • NRC Engage
  • Genome BC
  • Government of Manitoba
  • DFAIT Canada
  • MEDTEQ+
 

Biomark maintains collaborative studies with:

  • University of British Columbia
  • University of Manitoba
  • University of Victoria
  • University of Waterloo
  • University of Alberta
  • Institut Universitaire de Cardiologie et de Pneumologie de Quebec (ICUPQ)
  • University of Brescia

To expand our metabolomics studies, Biomark has engaged Bio banks across Canada and United States
.

Government

Funding and Grants for Cancer Research

  • Collaborative sponsored research grant in 2021 – The major portion of the funding is being provided by the Consortium for Industrial Research and Innovation in Medical Technology (MEDTEQ+) and Spark grant from the Canadian Cancer Society (CCS, grant # 707073), the Canadian Institutes of Health Research – Institute of Cancer Research (CIHR-ICR, grant # 0590008438), and Brain Canada Foundation.
  • Collaborative Health Research Projects (CHRP) funding in 2019 – The application was Canadian Institutes of Health Research (CIHR) in partnership with the Natural Sciences and Engineering Research Council of Canada (NSERC) and in collaboration with the Social Sciences and Humanities Research Council (SSHRC). BioMark is the industrial partner on the grant .
  • Going Global Innovation (GGI) – The Canadian Trade Commissioner Service – Offered funding to support BioMark to Japan and United States seeking partners for the purpose of establishing a collaborative R&D agreement in 2018
  • NSERC Engage Grants – 6 grants with professors from University of British Columbia, University of Victoria, University of Waterloo, University of Alberta and with University of Manitoba.
  • Mitacs – 7 projects have been supported by Mitacs program. Have commitment to fund additional post doctoral students for BioMark in coming year.
  • CSB – Commercialization Support for Business under Minister of Jobs and the Economy, Government of Manitoba
  • BIAP – Business Innovation Access Program under NRC-IRAP – Novel Recombinant Antibodies to Assess SSAT-1 Activity as a Biomarker for the Diagnosis of Cancer lead by Dr. Horacio Bach
  • NRC – IRAP Funding for 2013 – developing prototypes for cancer screening kits and IR system
  • Genome BC – Founding for Raman Quantification of Cancer Biomarkers for Early Lung Cancer Detection with Dr. Reuven Gordon and Dr. Fraser Hof from University of Victoria, British Columbia

Foundations

Foundations

  • Maunders McNeil Foundation provided financial support for clinical studies and publications in scientific peer reviewed papers by Dr. Andrew Maksymiuk and other researchers and investigators affiliated with BioMark Diagnostics Inc.

Achievements

Achievements, Awards and Recognitions for Cancer Research and Early Stage Cancer Detection Technology

Recent Achievements in 2021

  • Presented 2 posters on GBM at Canadian Cancer Research 6th biennial conference Nov 8 to 11, 2021. The posters entitled “Acetyl Amantadine as a Diagnostic Biomarker in Patients with Glioblastoma Multiforme (GBM)” and “Spermidine/spermine N1-acetyltransferase 1 (SAT1) – A Gene Target for Selective Sensitization of GB Cells”
  • BioMark participated at 3rd. annual International Society on Liquid Biopsy conference held on Oct 22, 2021. The presentation was on the role of metabolomics in liquid biopsy with particular focus on its dynamic early lung cancer liquid biopsy assay
  • BioMark secured advisory services and conditional funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support a research and development of its liquid biopsy molecular based test for the early detection and screening of lung cancer.
  • BioMark was awarded $825K under Medteq Impact program for the project titled “A Pan Canadian initiative for the development of a liquid biopsy assay for lung cancer screening”.
  • Dr. Wishart was awarded Spark funding from the Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition. The funding comes from the Canadian Cancer Society/Canadian Institutes of Health Research – Institute of Cancer Research, and Brain Canada Foundation
  • BioMark has an active portfolio of 8 family patents and intends to file new patents in 2021.
  • BioMark contributed four two scientific publications in 2021
  • Successfully obtained three major ethics approval and commissioning of new and expanded trials in 2021
  • Strategic collaboration with Phytronix in set up of a proprietary lab instrumentation was established to enhance the sensitivity and assay throughput for BioMark’s early lung cancer liquid biopsy lab developed test
  • A fully operational lab was established in Quebec City and highly trained lab manager and technicians hired
  • BioMark expanded its scientific, clinical and data science capabilities by recruiting leading experts into its senior management, lab operations and advisory team.
  • BioMark and IUCPQ has submitted an application under CqDM SynergiQc program for a multimodal study for $3.4 million funding
  • BioMark has signed several Non-Disclosure Agreements with distinguished lab / diagnostics / and institutions

Past Achievements

  • BioMark contributed two scientific publications in 2018
  • Successfully obtained three major ethics approval and commissioning of trials in 2018
  • BioMark has been short listed for CHRP’s application submitted by Drs. Don Miller, Thomas Klonish, Ted Lakowski, Marshall Pitz and Dr. David Wishart for a focused study to investigate SAT1 as a biomarker target for improved detection and clinical management of brain tumors.
  • BioMark expanded its scientific, clinical and data science capabilities by recruiting leading experts into its advisory team.
  • BioMark was granted several patents in Europe and China in 2018. BioMark continues to file trademark and patents in specific jurisdictions for all its patents.
  • New patents were filed as new panels of biomarkers were discovered. These patents will be critical as we stake our claims in the oncology diagnostic arena.
  • BioMark partnered with Alberta Machine Intelligence Institute to incorporate machine learning and generate artificial intelligence on its lung cancer retrospective studies. The goal was to improve assay performance by incorporating additional data.
  • Currently in development mode for a cost-effective mass spec system for quantification and qualification of markers with goal to further reduce cost per test
  • BioMark has signed several Non-Disclosure Agreements with distinguished lab / diagnostics / data analytic companies
  • BioMark and TMIC were part of the finalist in Genome Canada’s LSARP competition in 2018.
  • Going Global Award to meet with 3 major Japanese companies – Awarded by Global Affairs Canada – 2017
  • BioMark was invited and selected to present at various global Oncology and biomarker conferences and symposiums – London, Paris, Beijing and Boston.
  • Canadian Technology Accelerator Program – BioMark and the other 4 companies were selected as the first group of Canadian companies to go to Mission Bay in Silicon Valley
  • Regional Awards for New Technology – a prestigious award, supported by the National Research Council of Canada – BioMark Finalist
  • BioMark was selected for AdvaMed 2011 and 2013 in Washington DC funded by DFAIT

Executive Team & Advisors

Cross Pollinated, Balanced and Committed team since 2007.

Cancer Diagnostics

BioMark Pushing the Limit of Early Detection.

Awards, Grants, Recognitions

Genome BC in Oct 2013 – BioMark and Dr. Reuven funding for the use of Raman IR for cancer biomarker development.

Strategic Collaborations

Biopharmaceutical Research Inc. & University of Manitoba

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

early stage cancer detection - BioMark Diagnostics we believe cancer can be cured
early stage cancer detection - BioMark Diagnostics we believe cancer can be cured

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.